MA28364A1 - Formes polymorphes d'un agoniste gabaa - Google Patents

Formes polymorphes d'un agoniste gabaa

Info

Publication number
MA28364A1
MA28364A1 MA29278A MA29278A MA28364A1 MA 28364 A1 MA28364 A1 MA 28364A1 MA 29278 A MA29278 A MA 29278A MA 29278 A MA29278 A MA 29278A MA 28364 A1 MA28364 A1 MA 28364A1
Authority
MA
Morocco
Prior art keywords
polymorphic forms
gabaa agonist
gabaa
agonist
polymorphic
Prior art date
Application number
MA29278A
Other languages
English (en)
Inventor
Vincent Brett Cooper
Original Assignee
Lundbeck H
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28364(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck H, Lundbeck & Co As H filed Critical Lundbeck H
Publication of MA28364A1 publication Critical patent/MA28364A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA29278A 2004-01-30 2006-08-22 Formes polymorphes d'un agoniste gabaa MA28364A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
MA28364A1 true MA28364A1 (fr) 2006-12-01

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29278A MA28364A1 (fr) 2004-01-30 2006-08-22 Formes polymorphes d'un agoniste gabaa

Country Status (35)

Country Link
US (2) US7262300B2 (fr)
EP (2) EP2042505A1 (fr)
JP (1) JP4917440B2 (fr)
KR (1) KR101210361B1 (fr)
CN (1) CN1914212B (fr)
AR (1) AR047511A1 (fr)
AT (1) ATE414088T1 (fr)
AU (1) AU2005209473B2 (fr)
BR (1) BRPI0506858A (fr)
CA (1) CA2554536C (fr)
CO (1) CO5700743A2 (fr)
CY (1) CY1108647T1 (fr)
DE (1) DE602005010975D1 (fr)
DK (1) DK1713813T3 (fr)
DO (1) DOP2005000013A (fr)
EA (1) EA009413B1 (fr)
EC (1) ECSP066735A (fr)
ES (1) ES2314613T3 (fr)
GB (2) GB0402118D0 (fr)
HK (1) HK1096547A1 (fr)
HR (1) HRP20080614T3 (fr)
IL (1) IL176863A0 (fr)
MA (1) MA28364A1 (fr)
MX (1) MXPA06008595A (fr)
MY (1) MY139525A (fr)
NO (1) NO20063843L (fr)
NZ (1) NZ548191A (fr)
PE (1) PE20050769A1 (fr)
PL (1) PL1713813T3 (fr)
PT (1) PT1713813E (fr)
SI (1) SI1713813T1 (fr)
TW (1) TWI345972B (fr)
UA (1) UA87487C2 (fr)
WO (1) WO2005073237A2 (fr)
ZA (1) ZA200605307B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (fr) * 2005-01-28 2008-01-23 Merck & Co Inc Formes polymorphes d'un agoniste gabaa
DK1928405T3 (da) 2005-09-28 2014-12-15 Auris Medical Ag Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
PE20190338A1 (es) * 2015-07-17 2019-03-07 Ovid Therapeutics Inc Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
AU7405000A (en) 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
EP1399138B1 (fr) 2001-05-18 2006-02-08 Lonza Ag Procede de production de compositions solides de 3-hydroxy-3-methylbutyrate de sodium
AU2002338855B2 (en) 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
CN100491366C (zh) * 2002-09-03 2009-05-27 华晶基因技术有限公司 汉黄芩素用作治疗焦虑症的药物的用途
DE602004025808D1 (de) * 2003-06-25 2010-04-15 Lundbeck & Co As H Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005023256A1 (fr) 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Utilisation d'agonistes des recepteurs gabaa pour traiter les troubles auditifs, vestibulaires et de l'attention, le tremblement intentionnel et le syndrome des jambes sans repos
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EA200700102A1 (ru) 2004-06-29 2007-06-29 Х.Лундбекк А/С Лечение невропатической боли, фибромиалгии или ревматоидного артрита
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (fr) 2005-01-28 2008-01-23 Merck & Co Inc Formes polymorphes d'un agoniste gabaa
WO2006102093A1 (fr) 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Formes du gaboxadol, preparations comprenant ces formes, et methodes liees
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Also Published As

Publication number Publication date
CA2554536A1 (fr) 2005-08-11
ECSP066735A (es) 2006-10-31
AR047511A1 (es) 2006-01-25
EP2042505A1 (fr) 2009-04-01
KR20070007070A (ko) 2007-01-12
TWI345972B (en) 2011-08-01
JP4917440B2 (ja) 2012-04-18
US20050171142A1 (en) 2005-08-04
PE20050769A1 (es) 2005-10-04
EP1713813A2 (fr) 2006-10-25
DOP2005000013A (es) 2005-08-15
HK1096547A1 (en) 2007-06-01
US7262300B2 (en) 2007-08-28
CN1914212B (zh) 2010-10-06
NZ548191A (en) 2010-04-30
MXPA06008595A (es) 2006-08-28
DE602005010975D1 (de) 2008-12-24
EA009413B1 (ru) 2007-12-28
GB2410434A (en) 2005-08-03
CY1108647T1 (el) 2014-04-09
CA2554536C (fr) 2012-09-18
EP1713813B1 (fr) 2008-11-12
KR101210361B1 (ko) 2012-12-10
MY139525A (en) 2009-10-30
AU2005209473B2 (en) 2010-03-04
GB0402118D0 (en) 2004-03-03
CN1914212A (zh) 2007-02-14
AU2005209473A1 (en) 2005-08-11
CO5700743A2 (es) 2006-11-30
ATE414088T1 (de) 2008-11-15
DK1713813T3 (da) 2009-02-16
US8236958B2 (en) 2012-08-07
SI1713813T1 (sl) 2009-02-28
PT1713813E (pt) 2008-12-26
WO2005073237A3 (fr) 2005-10-20
GB0501847D0 (en) 2005-03-09
TW200534856A (en) 2005-11-01
US20070259912A1 (en) 2007-11-08
HRP20080614T3 (en) 2009-01-31
IL176863A0 (en) 2006-10-31
NO20063843L (no) 2006-08-29
ES2314613T3 (es) 2009-03-16
BRPI0506858A (pt) 2007-05-29
EA200601404A1 (ru) 2006-12-29
PL1713813T3 (pl) 2009-04-30
UA87487C2 (ru) 2009-07-27
WO2005073237A2 (fr) 2005-08-11
ZA200605307B (en) 2007-11-28
JP2007519697A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
MA28364A1 (fr) Formes polymorphes d'un agoniste gabaa
FR2868478B1 (fr) Structure de refroidissement d'un bloc-cylindres
FR2874407B1 (fr) Structure de refroidissement d'un bloc-cylindres
FR2868479B1 (fr) Structure de refroidissement d'un bloc-cylindres
NO20054868D0 (no) CaSr antagonist
ITMI20042238A1 (it) Composti per fluoropolirterei
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
EP1848420A4 (fr) Formes polymorphes d'un agoniste gabaa
MA28510B1 (fr) Sel de clopidogrel et formes polymorphes associees
FR2871397B1 (fr) Installation de conformation d'une aube creuse
FR2877088B1 (fr) Methode de decoincement d'un pneumatique
ITMI20041568A1 (it) "polimorfi di fexofenadina base"
FR2883016B1 (fr) Bloc fonctionnel destine aux troncons d'un abri telescopique
SE0400022D0 (sv) New compounds
SE0402103D0 (sv) Novel compounds
UA10465S (uk) Знак якості
SE0400254D0 (sv) New compounds
ES1054870Y (es) Conjunto de piezas para alero de tejado
ITSI20030001A1 (it) Dispositivo rimovibile per l'installazione rapida e
SE0401667D0 (sv) New compounds
SE0401658D0 (sv) New compounds
SE0402681D0 (sv) New compounds
SE0400102D0 (sv) New compounds
SE0400044D0 (sv) New compounds
SE0402509D0 (sv) New compounds